Cargando…
Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)
Autores principales: | Hodi, F Stephen, Ribas, Antoni, Daud, Adil, Hamid, Omid, Robert, Caroline, Kefford, Richard, Hwu, Wen-Jen, Gangadhar, Tara C, Joshua, Anthony M, Hersey, Peter, Weber, Jeffrey, Joseph, Richard W, Zarour, Hassane, Dronca, Roxana, Gammage, Linda, Hille, Darcy, Xue, Dahai, Kang, S Peter, Chun, Patrick, Ebbinghaus, Scot W, Perrone, Andrea, Wolchok, Jedd D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288385/ http://dx.doi.org/10.1186/2051-1426-2-S3-P103 |
Ejemplares similares
-
Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
por: Ayers, Mark, et al.
Publicado: (2015) -
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types
por: Gangadhar, Tara C, et al.
Publicado: (2015) -
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
por: Hamid, O, et al.
Publicado: (2019) -
An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015) -
Pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-023
por: Mateos, Maria-Victoria, et al.
Publicado: (2015)